Opinion

Video

Safety and Efficacy of HER2-Directed ADCs for NSCLC

Panelists discuss how the selection between fam-trastuzumab deruxtecan-nxki and ado-trastuzumab emtansine is guided by findings from pivotal trials like DESTINY-Lung01 and DESTINY-Lung02, real-world patient outcomes compared with clinical trial results, and the management of common treatment-related adverse events associated with these HER2-directed therapies.

Video content above is prompted by the following:

  • What factors guide the choice between fam-trastuzumab deruxtecan-nxki and ado-trastuzumab emtansine?
  • What key insights emerged from pivotal trials like the phase 2 basket DESTINY-Lung01and DESTINY-Lung02?
  • How do real-world patient outcomes compare with those seen in clinical trials?
  • What are the most common treatment-related adverse events observed with HER2-directed therapies, and how are they managed?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Dr Adela Perolla | Image Credit: - stock.adobe.com
4 experts are featured in this series.
4 experts are featured in this series.
2 experts in this video
4 experts are featured in this series.
2 experts in this video
Dr Ola Landgren
4 experts are featured in this series.
Dr Ola Landgren
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo